Author
Listed:
- David Peretz
(Institute for Neurodegenerative Diseases, University of California,)
- R. Anthony Williamson
(The Scripps Research Institute)
- Kiotoshi Kaneko
(Institute for Neurodegenerative Diseases, University of California,
National Institute of Neuroscience)
- Julie Vergara
(Institute for Neurodegenerative Diseases, University of California,)
- Estelle Leclerc
(The Scripps Research Institute)
- Gerold Schmitt-Ulms
(Institute for Neurodegenerative Diseases, University of California,)
- Ingrid R. Mehlhorn
(Institute for Neurodegenerative Diseases, University of California,)
- Giuseppe Legname
(Institute for Neurodegenerative Diseases, University of California,)
- Mark R. Wormald
(The Glycobiology Institute, University of Oxford)
- Pauline M. Rudd
(The Glycobiology Institute, University of Oxford)
- Raymond A. Dwek
(The Glycobiology Institute, University of Oxford)
- Dennis R. Burton
(The Scripps Research Institute
The Scripps Research Institute)
- Stanley B. Prusiner
(Institute for Neurodegenerative Diseases, University of California,
University of California
University of California)
Abstract
Prions are the transmissible pathogenic agents responsible for diseases such as scrapie and bovine spongiform encephalopathy. In the favoured model of prion replication, direct interaction between the pathogenic prion protein (PrPSc) template and endogenous cellular prion protein (PrPC) is proposed to drive the formation of nascent infectious prions1,2. Reagents specifically binding either prion-protein conformer may interrupt prion production by inhibiting this interaction. We examined the ability of several recombinant antibody antigen-binding fragments (Fabs) to inhibit prion propagation in cultured mouse neuroblastoma cells (ScN2a) infected with PrPSc. Here we show that antibodies binding cell-surface PrPC inhibit PrPSc formation in a dose-dependent manner. In cells treated with the most potent antibody, Fab D18, prion replication is abolished and pre-existing PrPSc is rapidly cleared, suggesting that this antibody may cure established infection. The potent activity of Fab D18 is associated with its ability to better recognize the total population of PrPC molecules on the cell surface, and with the location of its epitope on PrPC. Our observations support the use of antibodies in the prevention and treatment of prion diseases and identify a region of PrPC for drug targeting.
Suggested Citation
David Peretz & R. Anthony Williamson & Kiotoshi Kaneko & Julie Vergara & Estelle Leclerc & Gerold Schmitt-Ulms & Ingrid R. Mehlhorn & Giuseppe Legname & Mark R. Wormald & Pauline M. Rudd & Raymond A. , 2001.
"Antibodies inhibit prion propagation and clear cell cultures of prion infectivity,"
Nature, Nature, vol. 412(6848), pages 739-743, August.
Handle:
RePEc:nat:nature:v:412:y:2001:i:6848:d:10.1038_35089090
DOI: 10.1038/35089090
Download full text from publisher
As the access to this document is restricted, you may want to search for a different version of it.
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:nature:v:412:y:2001:i:6848:d:10.1038_35089090. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.